Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SLS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSELLAS raises $28.7M from warrant exercises, boosting cash to ~$136M
Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
Company received $28.7 million in April-May 2026 from warrant holders exercising rights to purchase common stock, increasing total cash position to approximately $135.8 million from $107.1 million at March 31.
Item 8.01 verify on EDGAR → -
medium
Share count increased to 196.6 million shares outstanding as of June 2, 2026, reflecting dilution from warrant conversions into common equity.
Item 8.01 verify on EDGAR →
Summary
SELLAS Life Sciences disclosed a significant capital raise through warrant exercises, bringing in $28.7 million during April and May 2026. Combined with the $107.1 million cash balance reported at quarter-end March 31, the company now holds approximately $135.8 million in cash and equivalents. This strengthens the biotech's runway to fund ongoing clinical programs and operations.
The capital raise came with dilution: the share count increased to 196.6 million shares outstanding as warrant holders converted their rights into common stock. For existing shareholders, this represents meaningful equity dilution but provides the company with non-dilutive-to-debt capital to advance its pipeline. Investors should monitor the company's quarterly cash burn rate in upcoming 10-Q filings to assess how long this expanded cash position extends the operational runway, particularly given the increased share base.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify